Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study


Journal

Turkish journal of haematology : official journal of Turkish Society of Haematology
ISSN: 1308-5263
Titre abrégé: Turk J Haematol
Pays: Turkey
ID NLM: 9606065

Informations de publication

Date de publication:
25 02 2021
Historique:
entrez: 25 1 2021
pubmed: 26 1 2021
medline: 6 3 2021
Statut: ppublish

Résumé

The defective interplay between coagulation and inflammation may be the leading cause of intravascular coagulation and organ dysfunction in coronavirus disease-19 (COVID-19) patients. Abnormal coagulation profiles were reported to be associated with poor outcomes. In this study, we assessed the prognostic values of antithrombin (AT) activity levels and the impact of fresh frozen plasma (FFP) treatment on outcome. Conventional coagulation parameters as well as AT activity levels and outcomes of 104 consecutive critically ill acute respiratory distress syndrome (ARDS) patients with laboratory-confirmed COVID-19 disease were retrospectively analyzed. Patients with AT activity below 75% were treated with FFP. Maximum AT activity levels achieved in those patients were recorded. AT activity levels at admission were significantly lower in nonsurvivors than survivors (73% vs. 81%). The cutoff level for admission AT activity was 79% and 58% was the lowest AT for survival. The outcome in those patients who had AT activity levels above 75% after FFP treatment was better than that of the nonresponding group. As well as AT, admission values of D-dimer, C-reactive protein, and procalcitonin were coagulation and inflammatory parameters among the mortality risk factors. AT activity could be used as a prognostic marker for survival and organ failure in COVID-19-associated ARDS patients. AT supplementation therapy with FFP in patients with COVID-19-induced hypercoagulopathy may improve thrombosis prophylaxis and thus have an impact on survival. Koagülasyon ve enflamasyon arasındaki etkileşim, koronavirüs hastalığı-19 (COVID-19) hastalarında damar içi pıhtılaşma ve organ disfonksiyonunun önde gelen nedeni olabilir. Anormal pıhtılaşma profillerinin kötü sonuçlarla ilişkili olduğu bildirilmiştir. Bu çalışmada antitrombin (AT) aktivite düzeylerinin prognostik değerini ve taze donmuş plazma (TDP) tedavisinin klinik sonlanım üzerine etkisini değerlendirdik. Laboratuvarda doğrulanmış COVID-19 hastalığı olan 104 kritik akut solunum sıkıntısı sendromu (ARDS) hastasının geleneksel pıhtılaşma parametreleri, AT aktiviteleri ve klinik sonlanımları geriye dönük olarak analiz edildi. AT aktivitesi <%75 olan hastalara TDP uygulandı ve bu hastalarda ulaşılan en yüksek AT aktiviteleri kaydedildi. Giriş AT aktivitesi seviyeleri, ölenlerde yaşayanlara göre önemli ölçüde düşük kaydedildi (%73 vs. %81). Sağkalım için giriş AT aktivitesi eşik değeri %79, en düşük AT aktivitesi eşik değeri %58 olarak bulundu. TDP uygulamasından sonra AT aktivite düzeyleri %75 ve üzerinde olan hastalardaki klinik sonlanım, <%75 olan hastalardan daha iyiydi. AT’nin yanı sıra giriş D-dimer, C-reaktif protein ve prokalsitonin değerleri, mortalite risk faktörleri arasında yer alan koagülasyon ve enflamasyon parametreleriydi. AT aktivitesi, COVID-19 ile ilişkili ARDS hastalarında sağkalım ve organ yetmezliği için prognostik belirteç olarak kullanılabilir. COVID-19’un neden olduğu hiperkoagülopatili hastalarda TDP ile antitrombin uygulaması, tromboz profilaksisini iyileştirebilir ve böylelikle sağkalımı olumlu yönde etkileyebilir.

Autres résumés

Type: Publisher (tur)
Koagülasyon ve enflamasyon arasındaki etkileşim, koronavirüs hastalığı-19 (COVID-19) hastalarında damar içi pıhtılaşma ve organ disfonksiyonunun önde gelen nedeni olabilir. Anormal pıhtılaşma profillerinin kötü sonuçlarla ilişkili olduğu bildirilmiştir. Bu çalışmada antitrombin (AT) aktivite düzeylerinin prognostik değerini ve taze donmuş plazma (TDP) tedavisinin klinik sonlanım üzerine etkisini değerlendirdik.

Identifiants

pubmed: 33486940
doi: 10.4274/tjh.galenos.2021.2020.0695
pmc: PMC7927448
doi:

Substances chimiques

Antithrombins 0
Fibrin Fibrinogen Degradation Products 0
Procalcitonin 0
fibrin fragment D 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

15-21

Commentaires et corrections

Type : CommentIn

Références

Crit Care. 2005;9(6):R596-600
pubmed: 16280058
FEBS Lett. 2001 Nov 23;508(3):313-7
pubmed: 11728442
Clin Appl Thromb Hemost. 2018 Sep;24(6):874-883
pubmed: 29514467
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
J Thromb Haemost. 2020 Jul;18(7):1747-1751
pubmed: 32302448
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
Transfusion. 1979 Sep-Oct;19(5):597-8
pubmed: 505534
Thromb Res. 2010 Jan;125(1):6-11
pubmed: 19782389
J Thromb Haemost. 2020 May;18(5):1023-1026
pubmed: 32338827
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Ann Thorac Surg. 1984 Jun;37(6):466-8
pubmed: 6732336
Thromb Res. 2020 Dec;196:308-312
pubmed: 32977128
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Blood. 2002 Jun 1;99(11):4015-20
pubmed: 12010802
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
J Thromb Haemost. 2020 Jul;18(7):1738-1742
pubmed: 32302438
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120
pubmed: 32172226
Blood. 2018 Feb 22;131(8):845-854
pubmed: 29255070
Lab Hematol. 2003;9(3):125-31
pubmed: 14521318
J Thromb Haemost. 2014 Sep;12(9):1470-9
pubmed: 24943516
Thromb Haemost. 2016 Apr;115(4):712-28
pubmed: 26676884
Br J Haematol. 2020 Sep;190(5):e286-e288
pubmed: 32516429

Auteurs

İlkay Anaklı (İ)

İstanbul University, İstanbul Faculty of Medicine, Department of Anesthesiology and Reanimation, İstanbul, Turkey

Perihan Ergin Özcan (P)

İstanbul University, İstanbul Faculty of Medicine, Department of Anesthesiology and Reanimation, İstanbul, Turkey

Özlem Polat (Ö)

İstanbul University, İstanbul Faculty of Medicine, Department of Anesthesiology and Reanimation, İstanbul, Turkey

Günseli Orhun (G)

İstanbul University, İstanbul Faculty of Medicine, Department of Anesthesiology and Reanimation, İstanbul, Turkey

Gülçin Hilal Alay (GH)

İstanbul University, İstanbul Faculty of Medicine, Department of Anesthesiology and Reanimation, İstanbul, Turkey

Verda Tuna (V)

İstanbul University, İstanbul Faculty of Medicine, Department of Anesthesiology and Reanimation, İstanbul, Turkey

Emre Çeliksoy (E)

İstanbul University, İstanbul Faculty of Medicine, Department of Anesthesiology and Reanimation, İstanbul, Turkey

Mehmet Kılıç (M)

İstanbul University, İstanbul Faculty of Medicine, Department of Anesthesiology and Reanimation, İstanbul, Turkey

Mutlu Mercan (M)

İstanbul University, İstanbul Faculty of Medicine, Department of Anesthesiology and Reanimation, İstanbul, Turkey

Achmet Ali (A)

İstanbul University, İstanbul Faculty of Medicine, Department of Anesthesiology and Reanimation, İstanbul, Turkey

Sevgi Beşışık (S)

İstanbul University, İstanbul Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Turkey

Figen Esen (F)

İstanbul University, İstanbul Faculty of Medicine, Department of Anesthesiology and Reanimation, İstanbul, Turkey

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH